FDA approves Xolremdi to treat rare immune disease WHIM syndrome

U.S. Food and Drug Administration(FDA)ApprovedXolremdi (mavorixafor)capsules are indicated for use in patients 12 years of age and older who have WHIM syndrome (warts, hypogammaglobulinemia, infection, and myelodysplasia). This marks an important milestone as the first FDA-approved drug to treat this rare disease.

WHIM syndrome is a rare genetic disorder that compromises the immune system, resulting in a reduced number of mature neutrophils and lymphocytes. It affects approximately 1 in 500 live births and can lead to recurrent infections, including potentially life-threatening bacterial and viral infections.

The approval of Key findings include:

XolremdiImproved absolute neutrophil counts and absolute lymphocyte counts, which are critical in fighting infections. Patients taking Xolremdi experienced counts above the infection risk threshold significantly longer than those taking placebo. Xolremdilowered infection scores by 40% over 52 weeks of treatment.

Common adverse reactions of Xolremdi include thrombocytopenia, rash, rhinitis, epistaxis, vomiting and dizziness. Because of the risk of fetal harm, it is important for women of childbearing age to use effective contraception. Xolremdi may also interact with certain medications, supplements, and grapefruit.

Xolremdi's application received multiple designations, including Priority Review, Fast Track, Rare Pediatric Disease and Orphan Drug designations, highlighting the urgent need and significant impact of this treatment for WHIM syndrome.

The approval of Xolremdi represents an important advance in addressing the unmet medical needs of patients with WHIM syndrome, providing a targeted therapy that improves immune function and reduces the risk of recurrent and life-threatening infections.